title: Anti-cancer efficacy of silybin derivatives -- a structure-activity relationship.
abstract: Silybin or silibinin, a flavonolignan isolated from Milk thistle seeds, is one of the popular dietary supplements and has been extensively studied for its antioxidant, hepatoprotective and anti-cancer properties. We have envisioned that potency of silybin could be further enhanced through suitable modification/s in its chemical structure. Accordingly, here, we synthesized and characterized a series of silybin derivatives namely 2,3-dehydrosilybin (DHS), 7-O-methylsilybin (7OM), 7-O-galloylsilybin (7OG), 7,23-disulphatesilybin (DSS), 7-O-palmitoylsilybin (7OP), and 23-O-palmitoylsilybin (23OP); and compared their anti-cancer efficacy using human bladder cancer HTB9, colon cancer HCT116 and prostate carcinoma PC3 cells. In all the 3 cell lines, DHS, 7OM and 7OG demonstrated better growth inhibitory effects and compared to silybin, while other silybin derivatives showed lesser or no efficacy. Next, we prepared the optical isomers (A and B) of silybin, DHS, 7OM and 7OG, and compared their anti-cancer efficacy. Isomers of these three silybin derivatives also showed better efficacy compared with respective silybin isomers, but in each, there was no clear cut silybin A versus B isomer activity preference. Further studies in HTB cells found that DHS, 7OM and 7OG exert better apoptotic activity than silibinin. Clonogenic assays in HTB9 cells further confirmed that both the racemic mixtures as well as pure optical isomers of DHS, 7OM and 7OG were more effective than silybin. Overall, these results clearly suggest that the anti-cancer efficacy of silybin could be significantly enhanced through structural modifications, and identify strong anti-cancer efficacy of silybin derivatives, namely DHS, 7OM, and 7OG, signifying that their efficacy and toxicity should be evaluated in relevant pre-clinical cancer models in rodents.
authors.affiliation: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
authors.forename: Chapla
authors.initials: C
authors.lastname: Agarwal
authors.forename: Ritambhara
authors.initials: R
authors.lastname: Wadhwa
authors.forename: Gagan
authors.initials: G
authors.lastname: Deep
authors.forename: David
authors.initials: D
authors.lastname: Biedermann
authors.forename: Radek
authors.initials: R
authors.lastname: Gažák
authors.forename: Vladimír
authors.initials: V
authors.lastname: Křen
authors.forename: Rajesh
authors.initials: R
authors.lastname: Agarwal
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D045325:HCT116 Cells; D006801:Humans; D008297:Male; D015394:Molecular Structure; D000077385:Silybin; D012838:Silymarin / Q000031:analogs & derivatives / Q000737:chemistry* / Q000494:pharmacology; D013329:Structure-Activity Relationship
chemical_list: C568966:7-O-galloylsilybin; D000970:Antineoplastic Agents; D012838:Silymarin; C515097:dehydrosilybin; D000077385:Silybin
references.citation: Int J Cancer. 2003 Sep 20;106(5):699-705
references.pmid: 12866029
references.citation: Carcinogenesis. 2007 Jul;28(7):1533-42
references.pmid: 17389612
references.citation: J Med Chem. 2011 Oct 27;54(20):7397-407
references.pmid: 21928794
references.citation: Curr Cancer Drug Targets. 2013 Jun;13(5):486-99
references.pmid: 23617249
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Invest New Drugs. 2007 Apr;25(2):139-46
references.pmid: 17077998
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8641-7
references.pmid: 15623648
references.citation: Cell Biochem Funct. 1997 Mar;15(1):27-33
references.pmid: 9075334
references.citation: Oncol Rep. 2004 Feb;11(2):493-9
references.pmid: 14719089
references.citation: Clin Cancer Res. 2002 Nov;8(11):3512-9
references.pmid: 12429642
references.citation: Integr Cancer Ther. 2007 Jun;6(2):130-45
references.pmid: 17548792
references.citation: Life Sci. 2002 Feb 8;70(12):1447-59
references.pmid: 11883719
references.citation: Curr Opin Investig Drugs. 2008 Jun;9(6):591-604
references.pmid: 18516759
references.citation: Cancer Metastasis Rev. 2010 Sep;29(3):447-63
references.pmid: 20714788
references.citation: Planta Med. 2007 Nov;73(14):1495-501
references.pmid: 17948171
references.citation: Int J Cancer. 2007 May 1;120(9):2028-33
references.pmid: 17230508
references.citation: Eur J Cancer. 1996 May;32A(5):877-82
references.pmid: 9081370
references.citation: Bioorg Med Chem. 2006 Jun 1;14(11):3793-810
references.pmid: 16466920
references.citation: Int J Radiat Biol. 1992 May;61(5):603-9
references.pmid: 1349624
references.citation: J Phys Chem A. 2008 Feb 7;112(5):1054-63
references.pmid: 18193843
references.citation: Prostate. 2010 Jun 1;70(8):848-55
references.pmid: 20127732
references.citation: Indian J Med Res. 2006 Nov;124(5):491-504
references.pmid: 17213517
references.citation: PLoS One. 2012;7(4):e34630
references.pmid: 22514647
references.citation: Eur J Med Chem. 2010 Mar;45(3):1059-67
references.pmid: 20036447
references.citation: Bioorg Med Chem. 2004 Nov 1;12(21):5677-87
references.pmid: 15465345
references.citation: Clin Cancer Res. 2006 May 1;12(9):2944-50
references.pmid: 16675592
references.citation: Cancer Res. 2005 May 15;65(10):4448-57
references.pmid: 15899838
references.citation: Anticancer Res. 2006 Nov-Dec;26(6B):4457-98
references.pmid: 17201169
references.citation: Integr Cancer Ther. 2007 Jun;6(2):110-9
references.pmid: 17548790
references.citation: Curr Med Chem. 2007;14(3):315-38
references.pmid: 17305535
references.citation: Anticancer Res. 2003 May-Jun;23(3B):2649-55
references.pmid: 12894553
references.citation: J Nat Prod. 2010 Apr 23;73(4):613-9
references.pmid: 20297826
references.citation: Am Fam Physician. 2005 Oct 1;72(7):1285-8
references.pmid: 16225032
references.citation: Free Radic Biol Med. 2009 Mar 15;46(6):745-58
references.pmid: 19138735